S3-E37.2 - Can Today's Medicines Cause Fibrosis Regression in Cirrhosis Patients?
Send us Fan Mail This week, Surfing the NASH Tsunami returns to a subject we have explored from time to time over the past two years: helping patients with cirrhosis. While the immediate stimulus for ...
23 Heinä 202211min
S3-E37.1 - Cirrhosis Screening & Diagnostic Tests
Send us Fan Mail This week, Surfing the NASH Tsunami returns to a subject we have explored from time to time over the past two years: helping patients with cirrhosis. While the immediate stimulus for ...
23 Heinä 20229min
S3-E37 - What Do We Know That Can Help NASH Cirrhosis Patients Today?
Send us Fan Mail Surfing the NASH Tsunami has explored issues of NASH cirrhosis since our earliest episodes in 2020. This episode integrates panelists with three different perspectives to consider the...
21 Heinä 202255min
S3-E36.5 - REGENERATE Redux: Clearing The Finish Line?
Send us Fan Mail On July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file a new NDA for obeticholic acid (OCA) in NASH...
17 Heinä 202213min
S3-E36.4 - REGENERATE Redux: Other Obeticholic Acid (OCA) Questions
Send us Fan Mail On July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file a new NDA for obeticholic acid (OCA) in NASH...
17 Heinä 202212min
S3-E36.3 - REGENERATE Redux: Safety and Tolerability With Obeticholic Acid
Send us Fan Mail On July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file a new NDA for obeticholic acid (OCA) in NASH...
16 Heinä 202212min
S3-E36.2 - REGENERATE Redux: What OCA Efficacy Results Mean For Patients
Send us Fan Mail On July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file a new NDA for obeticholic acid (OCA) in NASH...
16 Heinä 202214min
S3-E36.1 - REGENERATE Redux: Obeticholic Acid (OCA) Efficacy
Send us Fan Mail On July 7, Intercept Pharmaceuticals released new results from the continuation of the REGENERATE trial and announced their intent to file a new NDA for obeticholic acid (OCA) in NASH...
16 Heinä 202213min
